ArticleJournal of medical case reports2026
Autoimmune encephalitis induced by atezolizumab and bevacizumab therapy for advanced hepatocellular carcinoma: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtezolizumab, an immune checkpoint inhibitor (ICI), became available for treating hepatocellular carcinoma (HCC) in 2020. It is now widely used in combination with bevacizumab for advanced HCC. However, ICI has been reported to cause severe immune-related adverse events (irAEs), and reports in the treatment of HCC are still very rare. We report a case of autoimmune encephalitis as an irAE in a patient undergoing ICI therapy for HCC. CASE PRESENTATION: A 66-year-old Japanese man was diagnosed with multiple HCC in the parenchyma of both liver lobes. We initiated combination treatment with atezolizumab and bevacizumab. On day 8, the patient had symptoms of fever, diarrhea, and loss of appetite and was transferred to our hospital due to impaired consciousness on day 10. He was restless and incoherent. Analysis of cerebrospinal fluid revealed an elevated monocyte count. The patient was diagnosed with autoimmune encephalitis due to ICI and started treatment with methylprednisolone 1,000 mg for 3 days. On the second day of treatment, his consciousness improved dramatically, and he was discharged on day 13.
conclusionsThe frequency of ICI therapy will increase; therefore, it is necessary to understand the rare irAEs due to ICIs. Moreover, prompt diagnosis and early administration of steroids may contribute to a successful response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.